Heart-First approach may shield lung cancer patients from treatment side effects
NCT ID NCT04980716
First seen Nov 18, 2025 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests whether early, specialized heart monitoring and care can reduce heart problems in people with advanced lung cancer who are getting chemoradiation and immunotherapy. About 524 adults with stage III non-small cell lung cancer will be randomly assigned to receive either standard care or early heart-focused care guided by a non-invasive heart monitor. The goal is to see if this approach improves survival and lowers the risk of serious heart side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.